|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-7-28
|
|
pubmed:abstractText |
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. Historically, CLL patients have received prednisone- or chlorambucil-containing regimens, resulting in modest responses and a slim chance of long-term survival. The addition of purine nucleoside analogues, specifically fludarabine, to the armamentarium has significantly improved efficacy in treatment-naive or heavily pretreated CLL patients. Since the 1980s, fludarabine monotherapy has demonstrated an improvement in response over historical chemotherapeutic agents. Single-agent fludarabine therapy has expanded into a combination regimen containing cyclophosphamide and has further evolved to incorporate monoclonal antibodies. A review of the fludarabine literature shows that these advancements in fludarabine-containing therapy have enhanced the overall patient response with a potential increase in survival time, thus representing progress towards a superior treatment for CLL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1744-7666
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1641-51
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16872267-Administration, Oral,
pubmed-meshheading:16872267-Aged,
pubmed-meshheading:16872267-Animals,
pubmed-meshheading:16872267-Antibodies, Monoclonal,
pubmed-meshheading:16872267-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16872267-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16872267-Antibodies, Neoplasm,
pubmed-meshheading:16872267-Antineoplastic Agents,
pubmed-meshheading:16872267-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16872267-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16872267-Cyclophosphamide,
pubmed-meshheading:16872267-Drug Administration Schedule,
pubmed-meshheading:16872267-Drug Evaluation, Preclinical,
pubmed-meshheading:16872267-Humans,
pubmed-meshheading:16872267-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:16872267-Randomized Controlled Trials as Topic,
pubmed-meshheading:16872267-Survival Analysis,
pubmed-meshheading:16872267-Vidarabine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Fludarabine in chronic lymphocytic leukaemia.
|
|
pubmed:affiliation |
First Department of Internal Medicine, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany. thomas.elter@uk-koeln.de
|
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|
